Affordable Access

Publisher Website

Liposome-mediated delivery of iminosugars enhances efficacy against dengue virus in vivo.

Authors
Journal
Antimicrobial Agents and Chemotherapy
0066-4804
Publisher
American Society for Microbiology
Publication Date
Volume
56
Issue
12
Identifiers
DOI: 10.1128/aac.01554-12
Keywords
  • 1-Deoxynojirimycin
  • Animals
  • Antiviral Agents
  • Cell Survival
  • Dengue
  • Dengue Virus
  • Drug Carriers
  • Drug Delivery Systems
  • Gene Dosage
  • Humans
  • Imino Sugars
  • Liposomes
  • Macrophages
  • Mice
  • Rna
  • Viral
  • Real-Time Polymerase Chain Reaction
Disciplines
  • Medicine

Abstract

A key challenge faced by promising antiviral drugs, such as iminosugars, is in vivo delivery to achieve effective levels of drug without toxicity. Four iminosugars, all deoxynojirimycin (DNJ) derivatives-N-butyl DNJ (NB-DNJ), N-nonyl DNJ, N-(9-methoxynonyl) DNJ, and N-(6'-[4″-azido-2″-nitrophenylamino]hexyl)-1-DNJ (NAP-DNJ)-potently inhibited both the percentage of cells infected with dengue virus and release of infectious virus from primary human monocyte-derived macrophages, demonstrating their efficacy in primary cells. In a lethal antibody-dependent enhancement mouse model of dengue pathogenesis, free NB-DNJ significantly enhanced survival and lowered viral load in organs and serum. Liposome-mediated delivery of NB-DNJ, in comparison with free NB-DNJ, resulted in a 3-log(10) reduction in the dose of drug sufficient to enhance animal survival. The optimizing of the effective dose in this way could liberate the therapeutic potential of many cytotoxic antivirals against both dengue virus and a wide array of other viruses.

There are no comments yet on this publication. Be the first to share your thoughts.